Catalyst Pharmaceutical Partners to Present at 12th Annual BIO Investor Forum

Catalyst Pharmaceutical Partners to Present at 12th Annual BIO Investor Forum

CORAL GABLES, Fla., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases, today announced that
Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief
Operating Officer and Chief Scientific Officer, will present at the 12^th
Annual BIO Investor Forum being held at The Palace Hotel in San Francisco,
California, October 8-9. The presentation is scheduled for Tuesday, October
8^th at 9:00 am (PDT). The presentation materials will be posted at
www.catalystpharma.com in the Investors section under Events & Presentations.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial and recently received "Breakthrough Therapy Designation" from the U.S.
Food and Drug Administration (FDA). Catalyst is also developing a potentially
safer and more potent vigabatrin analog (designated CPP-115) to treat
infantile spasms, and epilepsy, as well as other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic stress
disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase
III trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse™ will expedite the development and review of
Firdapse™ by the FDA or the likelihood that the product will be found to be
safe and effective, whether an NDA for Firdapse™ will ever be accepted for
filing by the FDA, the timing of any such NDA filing or acceptance, whether
any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercialized, and those other factors
described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012
and other filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
 
Press spacebar to pause and continue. Press esc to stop.